78 results about "Serum markers" patented technology

The invention relates to the technical field of medical diagnosis, and discloses a DCM early noninvasive analysis method based on multi-radiomics and serum markers. Collecting image data through a multi-modal medical imaging device, and collecting serum marker data through a blood detection device; respectively generating a radiomics feature set and a serum marker time sequence feature set by using a multi-scale feature extraction algorithm and a time sequence analysis model; fusing the features by adopting a dynamic weighted fusion strategy to generate a joint feature matrix; inputting the model into a pre-trained multi-task deep learning model to predict a DCM risk probability; and finally, based on a genetic algorithm, optimizing the diagnosis decision tree and outputting an early DCM diagnosis result. The method is noninvasive and accurate, and can effectively improve the early diagnosis accuracy of DCM.

The invention relates to a method for constructing an HBV (Hepatitis B Virus) related HCC (Hepatitis C Chromatography) risk model by using an ESPL1 serum marker. The method comprises the following steps: firstly, identifying and extracting key oscillation characteristic indexes in an ESPL1 concentration curve through an improved time domain-frequency domain hybrid analysis system (TF-HySys) according to the fluctuation characteristic of the serum marker concentration on a time sequence; then, a dynamic probability coupling matrix (PCM) is constructed by utilizing the obtained oscillation characteristic indexes, preset auxiliary marker concentration / characteristics and clinical characteristic data; thirdly, constructing a differential equation inversion integration model (InDiMod) based on the PCM to carry out HCC risk modeling, and outputting a comprehensive dynamic risk integral (iDRS); secondly, establishing a'risk layering-threshold dynamic linkage system '(RT-DynLink) to carry out risk layering; and finally, integrating the above steps to develop an individual HCC risk trajectory generation and visual engine (TrajGen-Vis), and providing support for clinical intervention decision.

The invention discloses application of a bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-3-2 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for correcting intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-3-2 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, improve the level of serum markers in sarcopenia, regulate the homeostasis of intestinal flora so as to relieve muscular atrophy, prepare freeze-dried bacterial powder and enrich products for improving sarcopenia.

The invention relates to the field of biological detection, in particular to application of IGSF1 protein as a cardiac function recovery marker. The invention provides application of protein as a marker in preparation of a product for detecting and / or diagnosing heart failure with improved ejection fraction. The protein comprises one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4, and is characterized in that the protein comprises one or more of the IGSF1, the LIMS1, the MPP1, the PTX3, the SLC2A3, the FERMT3, the ARPC1B, the IGHG1 The invention provides a novel serum marker, the expression level of the novel serum marker can predict heart failure patients with reduced ejection fraction and heart function recovery potential with high precision, and the change of the novel serum marker is earlier than the change of ejection fraction. According to the invention, a non-invasive standardized detection process based on a serum sample is established, all levels of medical institutions are adapted, and early and non-invasive prediction of the heart function recovery potential of the heart failure patient is realized.

The invention discloses a silent pituitary ACTH cytoma identification method. The method comprises the following steps: determining a pituitary neuroendocrine tumor through imaging examination; a serum marker SAA (serum amyloid protein A) index is obtained through blood detection; constructing a silent pituitary ACTH cytoma recognition model by combining serum marker SAA indexes, age, gender, clinical symptoms and various hormone variable characteristics of pituitary; and identifying and judging the silent pituitary ACTH cytoma according to the identification model. The serum SAA is used as an index for identifying the silent pituitary ACTH cytoma, and the serum SAA is used as a mature serum detection index in clinical application, so that a doctor can accurately identify a high-risk subtype of the silent pituitary ACTH cytoma which is a pituitary neuroendocrine tumor, and can adjust an operation strategy according to factors such as invasiveness and recurrence risk of the tumor; therefore, the operation effect is improved, and patient prognosis is improved.

The utility model discloses a blood collection card, and belongs to the technical field of body fluid collection cards. Comprising a supporting clamping shell, a PVC bottom plate, a serum collecting pad, a buffering pad, a blood filtering pad and a cell blocking pad, and a mold strip is packaged in the supporting clamping shell; a collection window is arranged on the top surface of one end of the supporting clamping shell; a breaking weak part is arranged at the middle rear part of the supporting clamping shell; the die strip comprises the serum collecting pad which is adhered to the top surface of the PVC bottom plate; one end of the buffer pad is lapped to the top surface of one end of the serum collection pad; the other end of the buffer pad is adhered to the top surface of the PVC bottom plate; one end of the blood filtering pad is lapped to the top surface of one end of the buffer pad; the other end of the blood filtering pad is adhered to the top surface of the PVC bottom plate; one end of the cell blocking pad is lapped to the top surface of one end of the blood filtering pad; the other end of the cell barrier pad is adhered to the top surface of the PVC bottom plate; the blood collection card disclosed by the utility model can be used for separating serum from blood cells, and is suitable for in-vitro detection of serum markers.

The invention discloses a colorectal cancer diagnostic marker group based on expiration volatile organic compounds and application of the colorectal cancer diagnostic marker group. The colorectal cancer diagnostic marker group consists of six expiration volatile organic compounds, namely furfural, 2-methyl butane, valeric acid, methyl allyl sulfide, hexane and octanal. According to the method, expiration samples of 182 subjects are analyzed through TD-GC-MS / MS, machine learning is combined, the six expiration volatile organic compounds are screened out, the diagnosis AUC of the combination in a verification queue reaches 0.907, the accuracy rate is 0.806, and the combination is superior to a serum marker combination (AUC = 0.861). The invention further provides the BRS and a colorectal cancer noninvasive diagnosis and risk stratification system, and the BRS and the colorectal cancer noninvasive diagnosis and risk stratification system are used for achieving efficient prediction and risk stratification of the colorectal cancer. Compared with a traditional risk scoring model depending on clinical variables such as age, family history and lifestyle, the BRS provides unique metabonomics information, and the prediction accuracy is remarkably improved.

The invention belongs to the technical field of biology, and particularly relates to a detection method of a tumor serological marker. The application of the reagent for detecting the concentration of the sGRP78 protein in the serum of the breast cancer patient in preparation of a product for evaluating the curative effect of the breast cancer patient after neoadjuvant therapy is characterized in that the number of neoadjuvant therapy is four. In order to overcome the defects of dynamic monitoring deficiency, invasiveness, high cost and insufficient serum marker sensitivity in the existing neoadjuvant therapy metaphase evaluation of the breast cancer, the invention provides a detection kit, namely, the serum marker sGRP78 is monitored in the neoadjuvant therapy metaphase evaluation of the breast cancer, and the sensitivity of the serum marker sGRP78 in the neoadjuvant therapy metaphase evaluation of the breast cancer is improved. Therefore, a noninvasive, low-cost, high-sensitivity and high-specificity neoadjuvant therapy metaphase evaluation index is achieved.

The invention discloses a metabolic marker aldosterone for screening heat stress Hu sheep as well as a screening method and application thereof, and belongs to the technical field of livestock serum markers. The metabolic marker for screening the heat stress Hu sheep is aldosterone; the screening method comprises the following steps: (1) taking blood of known heat-sensitive Hu sheep or heat-resistant Hu sheep as a standard test sample, taking blood of Hu sheep to be detected as a detection sample, and centrifuging to obtain a serum sample; (2) detecting the aldosterone concentration in the serum sample; and (3) calculating the aldosterone concentration average value of the standard test sample, taking the calculated aldosterone concentration critical value as a reference level, if the aldosterone concentration of the detection sample is higher than the reference level, determining that the detection sample is a heat-resistant Hu sheep, and if the aldosterone concentration of the detection sample is lower than the reference level, determining that the detection sample is a heat-sensitive Hu sheep. The aldosterone is used as the marker for detection, has the characteristics of high accuracy and high sensitivity, and can be directly used as an evaluation index for distinguishing the heat-sensitive Hu sheep from the heat-resistant Hu sheep.

The present invention relates to a set of molecular markers for assessing preoperative perfusion impairment in acute aortic dissection type A, said serum markers being: L-Kynurenine (Kyn), or L-Tryptophan (Try), or the ratio Kyn / Try (KTR).

The application discloses application of a reagent for detecting a biomarker in preparation of a product for predicting ulcerative colitis disease activity or a product for diagnosing ulcerative colitis disease, and relates to the technical field of serological markers of inflammatory bowel disease. The serum CD105 of a UC patient is significantly higher than that of a healthy control group, and CD105 has a very high effect of diagnosing ulcerative colitis disease, and CD105 can distinguish disease activity from remission. Therefore, the application provides a novel serum marker which is convenient to sample, has good repeatability and can objectively reflect the colon mucosa inflammation load, and is expected to provide more accurate marker selection for UC disease activity prediction and UC diagnosis.

This invention discloses the application of the serum biomarker miR-206 in the preparation of Alzheimer's disease diagnostic products. This invention is the first to use the serum biomarker miR-206 in the effective and auxiliary diagnosis of Alzheimer's disease, demonstrating extremely high diagnostic performance. This invention lays the technical and data foundation for the development of stable and reliable Alzheimer's disease point-of-care testing kits or automated chemiluminescence detection systems and other in vitro diagnostic products. It has significant clinical application prospects in promoting the transformation of early screening and auxiliary diagnosis of Alzheimer's disease from reliance on complex imaging and cerebrospinal fluid examinations to convenient, non-invasive blood tests.

This invention discloses a method for constructing a cancer assessment model, as well as a cancer assessment system, media, and electronic device. The assessment model developed in this invention significantly improves the diagnostic efficacy of hepatitis B virus-related liver cancer, especially demonstrating excellent predictive performance in early-stage liver cancer and patients with negative serum biomarkers. Compared with single biomarkers and existing scoring models, the cancer assessment model constructed in this invention has significant advantages in comprehensive indicators such as AUC, sensitivity, and specificity. Although GP73, introduced in the model, has a negative coefficient, its synergistic effect with other biomarkers effectively improves diagnostic performance. The assessment model constructed in this invention provides a reliable tool for non-invasive prediction and early screening of liver cancer, and has significant clinical application value.

The invention discloses a pancreatic cancer diagnosis marker and application thereof, and belongs to the technical field of biological medicines, a serological marker for pancreatic cancer diagnosis is thymosin beta-10, namely Tbeta10, a biomarker for pancreatic cancer diagnosis is a gene TMSB10 for coding the Tbeta10, the gene is 9168 in an NCBI database, a qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, a qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2, the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.1, the qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, and the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2. Tbeta10 protein or TMSB10 gene high expression serves as a biomarker for diagnosis and poor prognosis of a pancreatic cancer patient, it is determined that the content of Tbeta10 in serum of the pancreatic cancer patient is remarkably increased, the Tbeta10 protein or TMSB10 gene high expression serves as a serum marker for diagnosis and curative effect and prognosis monitoring of the pancreatic cancer, and the total survival rate of the pancreatic cancer patient is reduced; the TMSB10 is used as a biomarker for poor prognosis of pancreatic cancer patients.

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

The invention relates to the technical field of laboratory medicine, in particular to application of IGSF3 as a serum marker in preparation of medicines for breast cancer diagnosis. The invention discovers that the expression level of serum IGSF3 in a metastatic breast cancer patient is obviously increased for the first time. The IGSF3 can be used as a serum marker for diagnosing breast cancer metastasis, the expression level of the serum IGSF3 in a metastatic breast cancer patient is remarkably improved compared with a healthy control person and a non-metastatic breast cancer patient, and ROC curve analysis shows that AUC is 0.799. The non-invasive auxiliary diagnosis of the metastatic breast cancer is carried out by using a small amount of serum samples, so that large-scale breast cancer screening is facilitated, and early discovery, early intervention and early treatment of the breast cancer are facilitated.

The invention discloses an oral lichen planus molecular subtype based on a serum protein marker. The molecular typing is based on a multi-center clinical queue, a new molecular typing is obtained by using transcriptome sequencing data through a Seed-Kmeans semi-supervised clustering algorithm, and a serum marker is further screened out through multiple omics data including the transcriptome sequencing data, proteome sequencing data and serum enzyme-linked immunosorbent assay experimental data. The method can be used for further judging molecular typing. The molecular typing can obviously improve the curative effect of the oral lichen planus medicine, and is beneficial to the realization of OLP individualized precision medical treatment.

This invention relates to the field of medical diagnostic technology and discloses a non-invasive early DCM analysis method based on multi-radiomics and serum biomarkers. The method involves acquiring image data using multimodal medical imaging equipment and serum biomarker data using blood testing equipment; generating radiomics feature sets and serum biomarker time-series feature sets using multi-scale feature extraction algorithms and temporal analysis models, respectively; fusing these features using a dynamic weighted fusion strategy to generate a joint feature matrix; inputting this matrix into a pre-trained multi-task deep learning model to predict the probability of DCM risk; and finally, optimizing the diagnostic decision tree based on a genetic algorithm to output the early DCM diagnostic result. This method is non-invasive, accurate, and can effectively improve the accuracy of early DCM diagnosis.

The invention relates to a serum marker for predicting glycolipid metabolism and a fat function. The serum marker is FBLN7. As a novel serological marker, the FBLN7 can specifically reflect changes of glycolipid metabolism and fat functions, changes of the serum level of the FBLN7 are closely related to occurrence and development of glycolipid metabolism disorder, and an important basis is provided for early diagnosis of diseases.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

To provide a new serum marker whose expression is restricted to the latent form of toxoplasmosis (bradyzoites / cysts). Also provided is an antibody that specifically binds to the new protein.SOLUTION: The present invention relates to a new Toxoplasma gondii protein, hereinafter referred to as BCLA, a new serum marker whose expression is restricted to the latent form of toxoplasmosis. This specific protein and its antigenic fragments can be used to detect autoantibodies in the serum of patients for the diagnosis of latent forms of toxoplasmosis. The invention also relates to derived antibodies generated by BCLA immunization that specifically bind to this new protein.SELECTED DRAWING: None

The present invention provides a method and related equipment for early warning of myelosuppression risk caused by treatment, which are applied to the field of data processing technology. The present application processes the multimodal data information of a target user to generate a target physiological state prediction factor; processes the target user's serum marker characteristic information to generate a myelosuppression influencing factor; processes the target user's lifestyle information to generate a myelosuppression risk adjustment factor; processes the myelosuppression influencing factor and the myelosuppression risk adjustment factor to generate dynamic risk parameter information for the target user; and processes the target physiological state prediction factor and the target user's dynamic risk parameter information based on a target high-dose methotrexate myelosuppression risk prediction model to generate a myelosuppression risk value and a bone marrow transplant risk level.

The present invention provides a biomarker for the detection of glioma microenvironment (TME), comprising a serum marker selected from any one or more of annexin A1 (ANXA1), annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2), and a pathological marker selected from any one or more of Annexin A1 (ANXA1), Annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2); the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and a phospholipase A2 group IIA (PLA2G2A), and the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and phospholipase A2 group IIA (PLA2G2A). The invention also provides an application of the biomarker in diagnosis of glioma. The invention provides an innovative idea and a biomarker for non-invasive diagnosis of glioma, and can be used for prognosis and malignant diagnosis of glioma.

The invention relates to application of SAA1 as a biomarker in preparation of an ovarian cancer diagnostic kit. The invention further provides application of a reagent for detecting the content of SAA1 protein in preparation of the ovarian cancer diagnostic kit and application of an SAA1 inhibitor in preparation of a medicine for treating ovarian cancer. A series of experiments show that myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues of an ovarian cancer patient are obviously gathered; sAA1 is elevated in an ovarian epithelial cancer (EOC) patient and is associated with a poor prognosis; sAA1 promotes proliferation of ovarian cancer cells in vitro; sAA1 released by ovarian cancer cells recruits MDSCs through a TLR2 / 4 receptor and promotes differentiation of the MDSCs. The invention innovatively provides a new treatment thought by deeply revealing the key effect of the SAA1-MDSCs in the ovarian cancer immunosuppression process, which undoubtedly has extremely important scientific significance and also shows huge value in clinical application.

This invention discloses an early ovarian cancer auxiliary diagnostic system based on multimodal fusion, belonging to the field of early ovarian cancer auxiliary diagnostic technology. It includes a data acquisition module, an image feature extraction module, a non-image feature extraction module, a multimodal fusion module, and a diagnostic output module. The data acquisition module acquires raw ultrasound images, serum biomarker test values, and clinical variable data; the image feature extraction module extracts image depth features; the non-image feature extraction module extracts non-image features; the multimodal fusion module dynamically calculates the attention weights of the two modalities and generates fused features; and the diagnostic output module outputs risk probability values. This invention overcomes the limitations of single-modal diagnosis by dynamically and adaptively fusing multimodal data such as ultrasound images, serum biomarkers, and clinical variables, significantly improving the accuracy of early ovarian cancer diagnosis, while also possessing interpretability and clinical deployment feasibility.

The invention provides a serum marker combination and an analysis system for predicting significant fibrosis of MASLD. Through an advanced targeted metabonomics technology and a machine learning algorithm, a serum metabolite diagnosis model (Inflammation Panel) specially used for diagnosing MASLD related significant fibrosis is developed and verified for the first time. The result analysis shows that the predicted AUC reaches 0.928 (95% CI: 0.835-0.978), the performance is obviously superior to the prediction efficiency of the current non-invasive diagnosis method, and the blank and the defect of the prior art in the aspect of non-invasive diagnosis of significant fibrosis (greater than or equal to F2) of a metabolic dysfunction related fatty liver disease (MASLD) patient are filled.

The present application relates to the field of biotechnology, in particular to the clinical application of SHOX2, PTGER4 methylation and serum marker cyfra21-1 combined detection in the diagnosis of malignant pleural mesothelioma. The present application first found that the combined detection of SHOX2, PTGER4 DNA methylation and serum marker cyfra21-1 can significantly improve the diagnosis rate of malignant pleural mesothelioma, reduce misdiagnosis, improve diagnostic accuracy, and improve patient survival rate.

The invention provides a serum marker combination and an analysis system for predicting significant liver lobular inflammation caused by MASLD. Through an advanced targeted metabonomics technology and a machine learning algorithm, a serum metabolite diagnosis model (Inflammation Panel) specially used for diagnosing MASLD-related significant intralobular inflammation (greater than or equal to I2) is developed and verified for the first time. The result analysis shows that the predicted AUC reaches 0.884 (95% CI: 0.791-0.957), the performance is obviously superior to the prediction efficiency of the traditional serum transaminase (AST / ALT), and the blank and deficiency in the aspect of noninvasive diagnosis of the significant liver lobular inflammation (greater than or equal to the I2 stage) of the metabolic dysfunction related fatty liver disease (MASLD) patient in the prior art are filled.

The present invention provides a method for the combined detection of the serum proteins GFAP, CNTN1, and NCAM1 for the early screening and diagnosis of gliomas. By detecting and analyzing the concentrations of CNTN1, GFAP, and NCAM1 proteins in patient serum, the results suggest that the combined use of these three serum proteins is of great significance for the early diagnosis of gliomas. The present invention also provides the use of GFAP, CNTN1, and NCAM1 in the preparation of reagents for the early screening and diagnosis of gliomas.

The invention discloses application of a novel intestinal cancer detection kit of RBM15, and relates to the technical field of biological detection, the application of the RBM15 as the intestinal cancer detection kit in CRC molecular markers is characterized in that 36 pairs of CRC tissues and para-carcinoma samples are detected through qRT-PCR, expression data of RBM15 and corresponding serum tumor clinical indexes in 36 cases of CRC clinical tissues are analyzed through Spearman correlation, and the RBM15 and the expression data of serum tumor clinical indexes in the CRC clinical tissues are analyzed. Based on CRC in a TCGA database and expression data of a normal sample, an ROC curve of RBM15 and other tumor related indexes is drawn, an AUC value is calculated, and it is shown that the diagnosis efficiency is superior to that of part of traditional serum markers. As a novel CRC molecular marker, the RBM15 provided by the invention has remarkable advantages in the aspect of constructing a high-sensitivity and high-specificity detection kit, can be used for early diagnosis and prognosis evaluation, provides a new target for developing a treatment strategy of targeting m6A modification, and has wide clinical application and transformation prospects.